These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1746705)

  • 41. CA 125 in monitoring chemotherapy of patients with ovarian cancer: early response to the treatment.
    Markowska J; Kopczyński Z; Manyś G; Szewierski Z
    Neoplasma; 1990; 37(6):687-92. PubMed ID: 2274087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The clinical significance of serum sialyl Tn antigen levels in patients with gynecologic tumors].
    Shimizu C; Inoue M; Ogawa H; Ueda G; Tanizawa O
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Nov; 42(11):1537-42. PubMed ID: 2273309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CA54/61 as a marker for epithelial ovarian cancer.
    Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
    Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemical evaluation of sialosyl-Tn antigens in various ovarian carcinomas.
    Ryuko K; Iwanari O; Kitao M; Moriwaki S
    Gynecol Oncol; 1993 May; 49(2):215-24. PubMed ID: 8504990
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of human ovarian tumor-associated antigens by sandwich enzyme immunoassay.
    Rao GS; Hanjani P
    Obstet Gynecol; 1988 Mar; 71(3 Pt 1):423-8. PubMed ID: 3279355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prognostic value of post chemotherapy serum CA 125 in epithelial ovarian cancer.
    Teeling M; McGing P; Carney DN
    Ir J Med Sci; 1989 Mar; 158(3):59-62. PubMed ID: 2745033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical evaluation of CA-50 in cases with colorectal cancer].
    Nishida O; Ohmori K; Shiroto H; Sawaguchi Y; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
    Gan No Rinsho; 1989 Apr; 35(5):605-8. PubMed ID: 2654447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
    Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
    Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunologic aspects of endometriosis].
    Kowalski W; Czekanowski R
    Ginekol Pol; 1989 Feb; 60(2):95-100. PubMed ID: 2680791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors.
    Vinokurov VL; Dudarev AL; Jurkova LE; Lapchenkov VI; Barbanel EJ
    Eur J Gynaecol Oncol; 1992; 13(2):205-8. PubMed ID: 1587297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does intraperitoneal CA-125 reflect disease status?
    Buller RE; Manetta A; Bloss JD; DiSaia PJ; Berman ML
    Gynecol Oncol; 1991 Jan; 40(1):66-9. PubMed ID: 1989917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.
    Rubin SC; Hoskins WJ; Hakes TB; Markman M; Reichman BS; Chapman D; Lewis JL
    Am J Obstet Gynecol; 1989 Mar; 160(3):667-71. PubMed ID: 2648838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CA 125 in the monitoring of response to chemotherapy of ovarian carcinoma.
    Quaranta M; Lorusso V; Coviello M; Micelli G; Casamassima A
    Int J Cancer Suppl; 1988; 3():68-70. PubMed ID: 3209302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.
    Rustin GJ; Gennings JN; Nelstrop AE; Covarrubias H; Lambert HE; Bagshawe KD
    J Clin Oncol; 1989 Nov; 7(11):1667-71. PubMed ID: 2681555
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative measurement of cancer antigen 125 (CA 125) in the differential diagnosis of ovarian tumors.
    Mogensen O; Mogensen B; Jakobsen A; Sell A
    Acta Oncol; 1989; 28(4):471-3. PubMed ID: 2789822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The value of estimating CA 125 in fluids from benign or malignant cysts, in the exudate and blood serum in women with ovarian cancer.
    Markowska J; Kopczyński Z; Szewierski Z; Markowski M; Niecewicz R
    Eur J Gynaecol Oncol; 1994; 15(1):29-32. PubMed ID: 8206067
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical value of sialyl SSEA-1 antigen in patients with ovarian cancer.
    Suzuki M; Ohwada M; Tamada T
    Gynecol Oncol; 1990 Mar; 36(3):371-5. PubMed ID: 1969379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma.
    Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
    Eur J Gynaecol Oncol; 1990; 11(2):127-33. PubMed ID: 2379512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating CA 15-3 antigen levels in non-mammary malignancies.
    Colomer R; Ruibal A; Genollà J; Salvador L
    Br J Cancer; 1989 Feb; 59(2):283-6. PubMed ID: 2930693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.